Business context and reporting period
The supplied filing is Ocuphire Pharma, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2022, not an Opus Genetics filing. Ocuphire (Nasdaq: OCUP) is a clinical-stage ophthalmic biopharmaceutical company developing Nyxol and APX3330; it had no approved products and no significant product revenue.
Financial performance and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Collaboration revenue | $0 | $0.1m | $0 | $0.1m |
| Operating expenses | $4.9m | $7.2m | $11.4m | $12.4m |
| Net loss | $4.9m | $7.1m | $11.5m | $46.2m |
| Operating cash used | Not separately stated for quarter | Not separately stated for quarter | $10.0m | $10.1m |
Quarterly G&A fell $1.6m year over year, largely because the prior-year quarter included investor settlement costs; R&D fell $0.7m, primarily reflecting trial completion and manufacturing timing. For the first half, lower G&A was partly offset by higher R&D, which rose $0.6m as clinical, manufacturing, regulatory and preclinical work increased. The much smaller first-half net loss versus 2021 mainly reflects the absence of a $33.8m warrant-liability fair-value expense recorded in 2021, rather than a comparable improvement in core operating performance.
At June 30, 2022, cash and cash equivalents were $17.0m, short-term investments $0.1m, current assets $17.9m and current liabilities $3.3m. Stockholders’ equity was $14.6m. The short-term loan was fully repaid in May 2022; the balance sheet reported no debt at quarter-end. No profit margin is meaningful given the absence of significant revenue and ongoing losses.
Cash decreased $7.5m in the first half, from $24.5m to $17.0m. Financing provided $2.5m, primarily from net ATM proceeds, partly offset by loan repayment. The company sold 1.21m shares under its ATM program for $3.1m gross proceeds in the first half. Common shares outstanding were 20.1m at June 30 and 20.58m as of August 9, 2022.
Outlook, commentary and risks
- Management said existing cash was expected to fund operations through the third quarter of 2023. The filing also states that substantial doubt exists about the company’s ability to continue as a going concern without additional financing; there is no assurance funding will be available on acceptable terms.
- Ocuphire expected to continue operating losses and increase spending as it advances clinical trials, manufacturing, regulatory preparation and potential commercialization. It expected to rely on equity or debt financing, collaborations, strategic alliances or licensing; equity financing could dilute shareholders.
- Nyxol: management reported positive top-line Phase 3 results for night-vision disturbances in May 2022 and anticipated an NDA submission for reversal of mydriasis in late 2022. A presbyopia Phase 3 trial was expected to begin in the second half of 2022. These are forward-looking plans, not outcomes established by this filing.
- APX3330: enrollment in the 103-patient ZETA-1 Phase 2b DR/DME trial was complete; top-line results were expected in the second half of 2022. July masked safety data were described as consistent with prior experience.
- Risks include clinical-trial and regulatory uncertainty, potential delays or cost increases from COVID-related supply-chain disruption and inflation, market volatility, and the need for further capital. Apexian license milestone payments of up to $11m for development/regulatory events and up to $20m for sales milestones, plus single-digit royalties on covered net sales, had not been triggered.
- The filing reported no material change to previously disclosed risk factors, no material legal proceedings, and effective disclosure controls as of June 30, 2022.
Most important facts to verify
- Confirm that Ocuphire Pharma, rather than Opus Genetics, is the intended company and filing.
- Verify the cash runway assumption and financing needs against subsequent filings and actual spending; the going-concern disclosure underscores funding risk.
- Check subsequent regulatory and clinical updates against the stated Nyxol NDA and trial plans and expected ZETA-1 results.
- Assess potential dilution from ATM sales and outstanding warrants and options; the filing lists millions of potential shares excluded from diluted loss per share as anti-dilutive.
- Review whether license milestones, royalties, contingencies or operating costs changed after June 30, 2022.